ENTITY
Walvax Biotechnology Co A

Walvax Biotechnology Co A (300142 CH)

44
Analysis
Health CareChina
Walvax Biotechnology Company Limited develops, manufactures and sells bio-pharmaceutical vaccination products. The Company's products include haemophilus influenzae type b conjugate vaccine and meningococcal group A,C bivalent polysaccharide conjugate vaccine.
more
Refresh
27 Mar 2024 18:18

Beijing Wantai Biological (603392 CH): Struggling to Make a Mark in Murky China HPV Vaccine Market

Beijing Wantai expects 70%+ decline in net profit in 2023 due to competition. Going ahead, competition is expected to intensify further in China...

Logo
359 Views
Share
26 Mar 2024 08:55

Pre-IPO Beijing Health Guard Biotechnology - The Story of the HPV Vaccine Is Not as Good as Imagined

The real China’s HPV vaccine market could be smaller-than-expected.After being included in National Immunization Program, vaccine business will be...

Logo
413 Views
Share
26 Jul 2023 08:55

CanSino Biologics (6185.HK/​688185.CH) - The Story Has Changed

MCV4's sales could be sluggish this year, so CanSino's investment logic has completely changed.Due to a lack of potential to become a great vaccine...

Logo
233 Views
Share
29 Mar 2023 08:55

CanSino Biologics (6185.HK) 2022 Results - It Is Time to Reassess CanSino and Its Future Prospects

CanSino had poor performance last year,but share price could bounce back in the next “sector resonance".There's no long-term investment value until...

Logo
272 Views
Share
26 Jan 2023 08:55

Pre-IPO CanSino Biologics - 2022 Annual Results May Be Ugly as MCV4 Commercialization Hit a Snag

CanSino plans to IPO in Switzerland. MCV4 commercialization obstruction will aggravate 2022 performance pressure after the dividend of COVID-19...

Logo
301 Views
Share
x